Please Wait.....
Report
CSL Limited (CSL:ASX) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 121 Pages I Quaintel Research
Report Summary
CSL Limited (CSL:ASX) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of CSL Limited's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about CSL Limited, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses CSL Limited's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of CSL Limited's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers CSL Limited's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares CSL Limited's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by CSL Limited, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
CSL Limited operates as a biotechnology company that researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccine products. CSL Limited operates in three main business segments: CSL Behring for plasma products, CSL Seqirus for influenza vaccines, and CSL Vifor for nephrology products. CSL Limited offers plasma products to treat bleeding disorders, immunodeficiencies, hereditary angioedema, and alpha-1 antitrypsin deficiency. It provides vaccines to prevent influenza. CSL also offers products for iron deficiency, dialysis, and chronic kidney diseases. The company develops gene therapies and recombinant proteins as well. Founded in 1916, the company is headquartered in Melbourne, Victoria, Australia.
CSL Limited in the News:-
- 14-Feb-2025 - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine
- 13-Feb-2025 - European Commission Approves CSL's ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- 07-Feb-2025 - CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
- 24-Jan-2025 - Australias Therapeutic Goods Administration (TGA) Approves Registration of CSLs ANDEMBRY (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks
- 13-Dec-2024 - CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the CSL Limited's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company CSL Limited:
CSL Limited Porter's Five Forces Analysis
CSL Limited VRIO Analysis
CSL Limited BCG Analysis
CSL Limited Segmentation, Targeting and Positioning (STP) Analysis
CSL Limited Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
CSL Limited - Key Company Facts 8
CSL Limited - Company Description 9
CSL Limited - Top Executives 10
CSL Limited- Head Office & Locations 12
Head Office - Country 12
CSL Limited - Products and Services 13
Products 13
Services 16
CSL Limited - Company's Mission and Vision 18
Mission 18
Vision 18
CSL Limited - Corporate Strategy 19
CSL Limited - Business Description 26
CSL Behring 27
CSL Seqirus 28
CSL Vifor 29
CSL Limited - ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 33
CSL Limited - SWOT Analysis 34
Overview 34
Strengths 36
Weaknesses 40
Opportunities 41
Threats 43
CSL Limited - PESTLE Analysis 44
Overview 44
Political Factors 46
Economic Factors 48
Social Factors 50
Technological Factors 51
Legal Factors 52
Environmental Factors 54
CSL Limited - Financial Deep Dive 56
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 56
Profit and Loss Statement 58
Summary of Profit and Loss Statement 58
Balance Sheet 60
Summary of Balance Sheet 60
Cash Flow Statement 62
Summary of Cash Flow Statement 62
Key Financial Ratio Analysis 64
CSL Limited - Ratio Charts 65
Activity Ratio Charts 65
Growth Ratios Charts 66
Leverage Ratio Charts 67
Liquidity Ratio Charts 67
Competing Players 69
Snapshot of Competing Players 70
AbbVie Inc 70
Key Company Facts 70
Company Description 70
AstraZeneca Plc 71
Key Company Facts 71
Company Description 71
Bayer Aktiengesellschaft (Bayer AG) 72
Key Company Facts 72
Company Description 72
Bristol-Myers Squibb Company 73
Key Company Facts 73
Company Description 73
GSK plc 74
Key Company Facts 74
Company Description 74
CSL Limited - In the News 75
14-Feb-2025 - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine 75
13-Feb-2025 - European Commission Approves CSL's ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) 76
07-Feb-2025 - CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B 78
24-Jan-2025 - Australia's Therapeutic Goods Administration (TGA) Approves Registration of CSL's ANDEMBRY (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks 80
13-Dec-2024 - CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) 82
24-Oct-2024 - Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships 82
24-Apr-2024 - CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy 85
17-Apr-2024 - Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" 85
28-Mar-2024 - Vafseo approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients 88
19-Mar-2024 - Ferinject approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure 88
07-Mar-2024 - CSL Adopts Regional/National Public Health Timetable on the Removal of B/Yamagata Seasonal Influenza Virus Strain 90
23-Feb-2024 - CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy 90
11-Feb-2024 - CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) 92
05-Feb-2024 - New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster 92
16-Jan-2024 - Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options 95
15-Jan-2024 - Swissmedic Authorises CSL's HEMGENIX (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B 97
03-Jan-2024 - CSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe 99
CSL Limited - Key Deals 101
11-Jun-2024 - CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU 101
01-May-2024 - CSL Seqirus and ARS Pharma sign agreement to commercialise neffy (adrenaline nasal spray) in Australia and New Zealand 102
12-Oct-2023 - CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites 104
04-Oct-2023 - Seven New CSL Global Research Acceleration Initiative Awardees Announced to Fast-Track Therapeutics Innovation 105
26-Sep-2023 - CSL Seqirus secures multi-year pandemic preparedness agreement as part of its continued partnership with the UK government 107
01-Mar-2023 - CSL Seqirus and Amarin sign licensing agreement to commercialise Vazkepa (icosapent ethyl) in Australia and New Zealand 109
12-Dec-2022 - CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics 110
01-Nov-2022 - CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology 112
26-Oct-2022 - CSL enters into Strategic Option and License Agreement with Translational Sciences 112
Appendix 114
Definitions 114
SWOT Analysis 114
PESTLE Analysis 114
Value Chain Analysis 114
ESG Spotlight 114
Financial Deep Dive 114
Financial Ratios - 115
Activity Ratios 115
Growth Ratios 116
Leverage Ratios 117
Liquidity Ratios 118
Market Ratios 119
Profitability Ratios 119
Research Methodology 120
Disclaimer 121
Contact Us 121
Tables
Table 1: CSL Limited - Company Facts
Table 2: CSL Limited - Digital Presence
Table 3: CSL Limited - Top Executives
Table 4: CSL Limited - Products
Table 5: CSL Limited - Services
Table 6: CSL Limited - Share Price Trend - Feb-2024 to Feb-2025
Table 7: CSL Limited - Ratio Analysis - 2021-2024
Table 8: CSL Limited - Competing Players
Table 9: Competing Players - AbbVie Inc - Key Company Facts
Table 10: Competing Players - AstraZeneca Plc - Key Company Facts
Table 11: Competing Players - Bayer Aktiengesellschaft (Bayer AG) - Key Company Facts
Table 12: Competing Players - Bristol-Myers Squibb Company - Key Company Facts
Table 13: Competing Players - GSK plc - Key Company Facts
Charts
Figure 1: CSL Limited- SWOT Analysis
Figure 2: CSL Limited - PESTLE Analysis
Figure 3: CSL Limited - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 4: CSL Limited - Profit and Loss Statement - 2021-2024
Figure 5: CSL Limited - Balance Sheet - 2021-2024
Figure 6: CSL Limited - Cash Flow Statement 2021-2024
Figure 7: CSL Limited - Activity Ratio Charts
Figure 8: CSL Limited - Growth Ratio Charts (Value %)
Figure 9: CSL Limited - Leverage Ratio Charts
Figure 10: CSL Limited - Liquidity Ratio Charts
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security